Transition policy
We provide a transition process consistent with 42 CFR §423.120(b)(3), which deals with access to covered prescription drugs under Medicare Part D.
The process includes a written description of how enrollees whose current drug therapies may not be included in the 2024 HAP covered drug list or the 2025 HAP covered drug list also known as a formulary, may receive a temporary supply of a nonformulary drug, as well as Part D drugs that are on the formulary but require prior authorization, step therapy or are subject to quantity limits under the HAP Medicare utilization management rules.
A meaningful transition period allows sufficient time for members to work with their health care provider to select an appropriate formulary alternative or to request a formulary exception based on medical necessity.
Transition policy eligibility
The transition policy applies to:
- New enrollees into prescription drug plans at the beginning of a contract year
- The transition of newly eligible Medicare beneficiaries from other coverage at the beginning of a contract year
- The transition of individuals who switch from one plan to another after the beginning of a contract year
- Enrollees residing in long-term care facilities
- Current enrollees affected by formulary changes from one contract year to the next
Transition policy facts
The following information applies to members who make use of our transition policy:
-
Transition fills in the outpatient (retail) setting
-
Transition fills in the long-term care setting
-
Emergency supplies and level of care changes
-
Transitions across contract years
-
Transition extensions
-
Cost sharing for transition fill
-
Protected-class medications
-
Member notification
-
Exception process